Publications
- Safety of vedolizumab and ustekinumab in the treatment of pregnant women with inflammatory bowel disease - a multicentre retrospective-prospective observational study2022 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study2022 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Cellular and humoral immune responses to SARS-CoV-2 vaccination in inflammatory bowel disease patients2022 | First Faculty of Medicine, Second Faculty of Medicine
- Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 - results from clinical practice2020 | First Faculty of Medicine
- First clinical experience with biosimilar adalimumab FKB327 in patients with inflammatory bowel disease2020 | First Faculty of Medicine
- Vedolizumab vs. Ustekinumab as second-line therapy in Crohn's disease in clinical practice2019 | First Faculty of Medicine
- Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort2018 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Infliximab Biosimilar (Remsima (TM)) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre2017 | First Faculty of Medicine
- Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort2017 | First Faculty of Medicine
Loading network view...